» Articles » PMID: 31737616

Bone Marrow Mesenchymal Stem Cells' Secretome Exerts Neuroprotective Effects in a Parkinson's Disease Rat Model

Overview
Date 2019 Nov 19
PMID 31737616
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is characterized by a selective loss of dopamine (DA) neurons in the human midbrain causing motor dysfunctions. The exact mechanism behind dopaminergic cell death is still not completely understood and, so far, no cure or neuroprotective treatment for PD is available. Recent studies have brought attention to the variety of bioactive molecules produced by mesenchymal stem cells (MSCs), generally referred to as the secretome. Herein, we evaluated whether human MSCs-bone marrow derived (hBMSCs) secretome would be beneficial in a PD pre-clinical model, when compared directly with cell transplantation of hBMSCs alone. We used a 6-hydroxydpomanie (6-OHDA) rat PD model, and motor behavior was evaluated at different time points after treatments (1, 4, and 7 weeks). The impact of the treatments in the recovery of DA neurons was estimated by determining TH-positive neuronal densities in the and fibers in the striatum, respectively, at the end of the behavioral characterization. Furthermore, we determined the effect of the hBMSCs secretome on the neuronal survival of human neural progenitors , and characterized the secretome through proteomic-based approaches. This work demonstrates that the injection of hBMSCs secretome led to the rescue of DA neurons, when compared to transplantation of hBMSCs themselves, which can explain the recovery of secretome-injected animals' behavioral performance in the staircase test. Moreover, we observed that hBMSCs secretome induces higher levels of neuronal differentiation. Finally, the proteomic analysis revealed that hBMSCs secrete important exosome-related molecules, such as those related with the ubiquitin-proteasome and histone systems. Overall, this work provided important insights on the potential use of hBMSCs secretome as a therapeutic tool for PD, and further confirms the importance of the secreted molecules rather than the transplantation of hBMSCs for the observed positive effects. These could be likely through normalization of defective processes in PD, namely proteostasis or altered gene transcription, which lately can lead to neuroprotective effects.

Citing Articles

"Cellularity as a predictive tool for mesenchymal stem cell concentration in bone marrow concentrates: Implications for regenerative medicine".

Labarre K, Grathwol P, Zimmermann G Bone Rep. 2024; 24:101820.

PMID: 39691445 PMC: 11650265. DOI: 10.1016/j.bonr.2024.101820.


Current progression in application of extracellular vesicles in central nervous system diseases.

Zhang X, Huang J, Ni X, Zhu H, Huang Z, Ding S Eur J Med Res. 2024; 29(1):15.

PMID: 38173021 PMC: 10763486. DOI: 10.1186/s40001-023-01606-5.


Modulating Stress Proteins in Response to Therapeutic Interventions for Parkinson's Disease.

Silvestro S, Raffaele I, Mazzon E Int J Mol Sci. 2023; 24(22).

PMID: 38003423 PMC: 10671288. DOI: 10.3390/ijms242216233.


Treating Parkinson's Disease with Human Bone Marrow Mesenchymal Stem Cell Secretome: A Translational Investigation Using Human Brain Organoids and Different Routes of In Vivo Administration.

Mendes-Pinheiro B, Campos J, Marote A, Soares-Cunha C, Nickels S, Monzel A Cells. 2023; 12(21).

PMID: 37947643 PMC: 10650433. DOI: 10.3390/cells12212565.


Potential Utilisation of Secretome from Ascorbic Acid-Supplemented Stem Cells in Combating Skin Aging: Systematic Review of A Novel Idea.

Wahyuningsih K, Pangkahila W, Weta I, Widiana I, Wahyuniari I Cell J. 2023; 25(9):591-602.

PMID: 37718762 PMC: 10520989. DOI: 10.22074/cellj.2023.1995999.1253.


References
1.
Song C, Kanthasamy A, Jin H, Anantharam V, Kanthasamy A . Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration. Neurotoxicology. 2011; 32(5):586-95. PMC: 3407036. DOI: 10.1016/j.neuro.2011.05.018. View

2.
Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E . The ubiquitin pathway in Parkinson's disease. Nature. 1998; 395(6701):451-2. DOI: 10.1038/26652. View

3.
Nicholas A, Lubin F, Hallett P, Vattem P, Ravenscroft P, Bezard E . Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem. 2008; 106(1):486-94. DOI: 10.1111/j.1471-4159.2008.05417.x. View

4.
Chen L, Thiruchelvam M, Madura K, Richfield E . Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol Dis. 2006; 23(1):120-6. DOI: 10.1016/j.nbd.2006.02.004. View

5.
Axelsen T, Woldbye D . Gene Therapy for Parkinson's Disease, An Update. J Parkinsons Dis. 2018; 8(2):195-215. PMC: 6027861. DOI: 10.3233/JPD-181331. View